New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network
This is a paid press release. Contact the press release distributor directly with any inquiries.

New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network

FMW Media Works Corp
FMW Media Works Corp

Airings start on Bloomberg TV on Saturday, October 14, 2023, at 6:30 PM ET, followed by the FOX Business Network show on Sunday, October 15, 2023, at 3:30 PM ET

New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network

Episodes 521/522: 1).Vincerx Pharma, Inc.  (NASDAQ: VINC) ($VINC) 2). Surf Air Mobility, Inc. (NYSE: SRFM) ($SRFM) 3). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 4). Mangoceuticals, Inc. (NASDAQ: MGRX) ($MGRX). 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). 6). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) - https://www.newtothestreet.com/
Episodes 521/522: 1).Vincerx Pharma, Inc. (NASDAQ: VINC) ($VINC) 2). Surf Air Mobility, Inc. (NYSE: SRFM) ($SRFM) 3). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 4). Mangoceuticals, Inc. (NASDAQ: MGRX) ($MGRX). 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). 6). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) - https://www.newtothestreet.com/
New to The Street airs on three major cable networks.

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- New to The Street, an FMW Media business show production, will air its corporate interviews, episodes 521 and 522, as Sponsored Programming on Bloomberg TV and FOX Business Network.

Bloomberg TV airs Episode 521 as a sponsored programming Saturday, October 14, 2023, at 6:30 PM ET, featuring the following five (5) Corporate Guests:

1). Biopharmaceutical – Vincerx Pharma, Inc.'s (NASDAQ: VINC) ($VINC) interview with Alex Seelenberger, Chief Financial Officer.

2). Air Travel Electrification – Surf Air Mobility, Inc.'s (NYSE: SRFM) ($SRFM) interviews with Stan Little, Chief Executive Officer, and Sudhin Shahani, Founder.

3). Pet Health – PetVivo Holdings, Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) interviews with John Lai, CEO & President, and Judd Spodek, Owner/Trainer, Sit Happens, Inc.

4). "Breaking it Down" Segment -TV Host Ana Berry with Jacob Cohen, Chief Executive Officer of Mangoceuticals, Inc. (NASDAQ: MGRX) ($MGRX).

5). "Sekur Privacy & Sekur Security Segment The Weekly Hack" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®).

FOX Business Network airs Episode 522 as a sponsored programming Sunday, October 15, 2023, at 3:30 PM ET, featuring the following four (4) Corporate Guests:

1). InsurTech Company - Reliance Global Group, Inc.'s (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) interviews with Grant Barra, Senior Vice-President Operations and Eddie Larson, Agency Partner.

2). Pet Health – PetVivo Holdings, Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) interviews with John Lai, CEO & President, and Judd Spodek, Owner/Trainer, Sit Happens, Inc.

3). Air Travel Electrification – Surf Air Mobility, Inc.'s (NYSE: SRFM) ($SRFM) interviews with Stan Little, Chief Executive Officer, and Sudhin Shahani, Founder.

4). "Sekur Privacy & Sekur Security Segment The Weekly Hack" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®).

From the Nasdaq MarketSite Studio, New to The Street airs TV Host Jane King's interview with Alex Seelenberger, Chief Financial Officer of Vincerx Pharma, Inc. (NASDAQ: VINC) ($VINC). As a clinical-stage biopharmaceutical Company, Vincerx leverages its oncology expertise, focusing on developing new and advanced novel cancer drugs. Chemotherapies and radiation treatments are incredibly harmful to patients trying to beat cancer. These historical treatments come with many harmful toxic side effects where patients weigh the options over quality of life or life itself. Alex informs viewers about an upcoming class of drug treatments called antibody-drug conjugates (ADCs). These drugs target cancer, attaching and killing those cells. Unfortunately, FDA-approved ADCs in the marketplace still have risks, where toxicity still occurs, killing and destroying good cells/tissues. Vincerx's world-class management and scientific teams with decades of experience, numerous drug approvals, and regulatory expertise are developing next-generation ADCs that aggressively attack targeted cancer cells but dramatically diminish toxicity and healthy cell/tissue destructions. The Company's drug pipeline includes ADCs and small molecule drug conjugate (SMDC), all under development to combat different cancers with expected positive life-changing results for cancer patients. VIP236, an SMDC under development for treating advanced/metastatic solid tumors, has shown great lab results, and the developmental drug is in FDA Phase I clinical trial. Management expects data from the clinical to be forthcoming in 2024. Management recently entered an FDA Phase I clinical on VIP943, an ADC for treating certain types of leukemia, and they expect the published results of the study to come sometime in 2024. The Company is developing VIP924, a treatment for multiple malignancies, and VIP512, a combination drug agent. Vincerx Pharma is aggressively addressing the unmet medical needs of patients with cancer through novel and innovative drug treatments. The on-screen QR code is available during the show; download or visit Vincerx Pharma, Inc. - https://vincerx.com/. The interview will air as a sponsored programming on Bloomberg TV, episode 521, Saturday, October 14, 2023, at 6:30 PM ET.